| Christina Bruenderman, | |
|
1825 Margaret St, Cape Girardeau, MO 63701-2321 | |
| (573) 270-2791 | |
| Not Available |
| Full Name | Christina Bruenderman |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1825 Margaret St, Cape Girardeau, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023293180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2007015745 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christina Bruenderman, 1825 Margaret St, Cape Girardeau, MO 63701-2321 Ph: (573) 270-2791 | Christina Bruenderman, 1825 Margaret St, Cape Girardeau, MO 63701-2321 Ph: (573) 270-2791 |
News Archive
Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
The rule, which have been delayed several times already, "requires businesses offering credit to come up with a written policy for finding, preventing and dealing with identity theft." The rule is now scheduled to be implemented Dec. 31.
A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient's own molecular profile - warehoused in a database of thousands of patient-donated biological tissue or tumor samples - to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly.
About one in 35 adult Americans is at high risk of coronary heart disease, meaning they have a greater than 20 percent chance of developing heart disease within 10 years, and about one in six has a 10-year risk that is greater than 10 percent, according to a new study in the May 19, 2004 issue of the Journal of the American College of Cardiology.
› Verified 4 days ago
Jackie A. Jones, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3433 Glenview Dr, Cape Girardeau, MO 63701 Phone: 573-335-8010 | |
Rachel Hearnes August, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1910 Grandview Dr, Cape Girardeau, MO 63701 Phone: 573-233-5481 | |
Audrey Farnham, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1910 Whitener St, Cape Girardeau, MO 63701 Phone: 573-334-2923 | |
Julie Spooler, M.A.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2561 Cobblestone Ct, Cape Girardeau, MO 63701 Phone: 573-335-9182 | |
Mrs. Regina Brucette Mcelroy, SPEECH THERAPIST Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 254 E Lake Dr, Cape Girardeau, MO 63701 Phone: 573-335-8031 | |
Miss Laura Ellen Schuch, M.A-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2606 Gardenia St, Cape Girardeau, MO 63703 Phone: 573-332-8863 |